Hypertension


  • Hypertension is diagnosed with a clinic BP ≥140/90mmHg, confirmed with an ambulatory or home BP ≥135/85mmHg
  • It is a common chronic disease, affecting 50% of those >65yrs old


Stage of hypertension Clinic BP (mmHg) Home/ambulatory BP (mmHg)
Stage 1 ≥140/90 ≥135/85
Stage 2 ≥160/100 ≥150/95
Stage 3 (severe) ≥180/120 N/A

  • Of note, the stage 3 diastolic threshold is 120mmHg in UK guidance but European and American guidelines use 115mmHg

  • Essential (primary) hypertension: 95%

  • Secondary hypertension: 5%
    • Renal disease e.g. renal artery stenosis, other renal comorbidity
    • Endocrine disease e.g. Conn's syndrome, phaeochromocytoma, Cushing's syndrome, hyperthyroidism, acromegaly
    • Vascular disease e.g. coarctation of the aorta
    • Drug-induced e.g. steroids, sympathomimetics
    • Pregnancy-related e.g. pre-eclampsia

  • Systolic BP rises continuously with age
  • Diastolic BP plateaus in late-middle age, and then may decrease
  • Pulse pressure therefore rises

  • Pulse-pressure hypertension has gained prominence as a risk factor for MI/stroke
  • The raised pulse pressure induces stress forces on the vascular tree and causes endothelial dysfunction and plaque rupture
  • Dysfunction in the autonomic nervous system and RAAS is thought to play a key role

Autonomic nervous system

  • Once hypertension is established, the baroreceptors 'reset' to the new level causing persistent hypertension
  • Patients may therefore have exaggerated sympathetic responses to stressors and exogenous vasopressors

RAAS

  • In some patients RAAS disorders contribute to hypertension
    • Renin activity is normal or increased in 75% of hypertensive patients, even though it should be decreased due to negative feedback
  • There may also be an impaired natriuretic response to volume excess

  • Once hypertension is established it becomes self-propagating due to:
    • Baroreceptor resetting
    • Vascular remodelling: luminal narrowing increases vascular resistance
    • LV hypertrophy

  • Chronic arterial hypertension produces end-organ damage, particularly cardiac, renal and cerebral (see next section)

Cardiovascular

  • Chronic HTN causes arterial/arteriolar wall stress
  • Endothelial dysfunction ensues and endogenous NO function is impaired
  • This leads to:
    • Atherosclerotic plaque formation
    • Accelerated aneurysm formation

  • The increased myocardial wall tension causes concentric LV hypertrophy
    • Poorer diastolic relaxation leads to impaired diastolic blood flow and myocardial ischaemia
    • This process is accelerated by atherosclerosis
    • Eventually, LV failure occurs

Cardiovascular sequelae
LV hypertrophy
Diastolic dysfunction
LV failure
Atherosclerotic coronary artery disease
Coronary artery dissection
Aortic dissection
Aortic aneurysms
Rupture of clot/uncontrolled surgical bleeding

Neurological/cerebrovascular

  • Cerebrovascular atherosclerosis leads to shifting of the autoregulatory curve, predisposing to haemorrhagic and watershed strokes
  • Carotid artery stenosis can lead to embolic events and global ischaemia from hypotension, predisposing to ischaemic and haemorrhagic strokes

Cerebrovascular sequelae
Vertebral artery dissection
Impaired cognition
Hypertensive encephalopathy e.g. PRES
Haemorrhagic stroke

Renal

  • Atherosclerosis of the renal vasculature leads to ischaemia, with:
    • Tubular injury
    • Glomerular atrophy
    • Nephropathy and renal failure
  • Renovascular autoregulation is defective/shifts to a higher pressure, leading these patients to be more susceptible to hypotension

Renal sequelae
Glomerulosclerosis
Renal tubular ischaemia
Progressive renal failure


NICE guidelines

  • Patients should receive lifestyle advice and drug treatment if they have:
    • Stage 2 hypertension or above, or
    • Stage 1 hypertension with additional cardiovascular risk: target organ damage, established cardiovascular disease, renal disease, diabetes or a 10-year cardiovascular risk ≥10%

  • Step 1
    • If the patient has T2DM, or is <55yrs and not of Black African or African-Caribbean family origin, then first line treatment is an ACE-I or ARB
    • If the patient does not have T2DM and is >55yrs or of Black African or African-Caribbean family origin, then first line treatment is a calcium channel blocker

  • Step 2
    • Add a second agent from ACE-I/ARB, calcium channel blocker or thiazide-like diuretic, depending on which drug the patient is already on

  • Step 3
    • ACE-I/ARB and calcium channel blocker and thiazide-like diuretic

  • Step 4
    • Confirm adherence to existing treatment
    • K+ ≤4.5 → spironolactone
    • K+ >4.5 → ɑ-blocker or β-blocker
    • Seek expert help

The hypertensive inpatient


Associations of inappropriately treating hypertension in inpatients
Excessive reductions in BP
Higher rates of AKI
Higher rates of myocardial injury
Higher rates of ischaemic neurovascular events
Drug-related adverse events
Intensification of outpatient anti-hypertensive regimens but
no long-term improvements in BP control or cardiovascular event risk
Increased risk of re-admission or
serious adverse event within 30 days
Longer duration of inpatient stay


Perioperative management of the patient with hypertension


Principles

  • The aim is to balance the short-term perioperative risk of hypertension against the harms of cancelling or postponing surgery
  • There is no clear evidence that stage 1 or 2 hypertension without target organ damage increases perioperative cardiovascular risk
  • There is no evidence that delaying surgery to optimise BP is beneficial

  • Guidance applies primarily to elective adult surgery, and does not cover emergency, obstetric, paediatric or niche (e.g. phaeochromocytoma surgery) settings

Thresholds for proceeding with elective surgery

  • Primary care should ideally document a BP from the preceding 12 months in the referral letter
  • GP, home or ambulatory readings are preferred to hospital clinic readings

Setting Clinic BP (mmHg) Home/ambulatory BP (mmHg) Action
Primary care
(within 12 months)
<160/100 <155/95 Proceed; secondary care should accept these readings
Primary care
(within 12 months)
≥160/100 ≥155/95 Treat before non-urgent referral
Pre-op assessment clinic
(no primary care reading)
<180/120 <175/115 Proceed; ask GP to reassess BP
Pre-op assessment clinic
(no primary care reading)
≥180/120 ≥175/115 Postpone; refer to GP for assessment and management

  • Elective surgery should therefore proceed unless the clinic BP is ≥180/120mmHg (stage 3)
  • If stage 3 hypertension is found at pre-operative assessment:
    • Exclude a hypertensive crisis
    • Arrange out-of-office BP measurements within 7 days
    • Red flag signs or symptoms of accelerated hypertension warrant same-day specialist assessment
    • For clinically urgent surgery (e.g. cancer surgery) a consensus decision should be made between anaesthetist, surgeon, patient ± perioperative physician

  • Patients who decline treatment, or who have persistent hypertension despite all appropriate attempts at control, may proceed following documented shared decision-making

History, examination and investigations

  • Establish diagnosis of hypertension and current treatment, including efficacy and side-effects
  • Establish presence of commonly coexisting comorbidities e.g. diabetes mellitus, IHD, CKD

  • Investigate end-organ effects
    • Cardiovascular: ECG ± TTE
    • Cerebrovascular e.g. previous TIA/stroke
    • Renal: U&E (especially if on diuretics or ACE-I/ARB); urine dipstick for haematuria or proteinuria

  • A pulse pressure >62mmHg is associated with an increased incidence of myocardial injury in the first 30 post-operative days

Patients at increased risk of perioperative BP fluctuations
BP-related Comorbidities affected by BP
Consistently >180/120mmHg Ischaemic heart disease
Untreated hypertension Cerebrovascular disease
Evidence of target organ damage Peripheral arterial disease
≥4 drugs required to control BP Diabetes
Postural hypotension CKD stages 3-5

Optimisation

  • Patients not on treatment who require pre-operative BP reduction:
    • First line: calcium channel blocker e.g. amlodipine 5mg, titrated to 10mg after 2 weeks
    • Markedly raised BP or high cardiovascular risk: CCB + ARB e.g. amlodipine 5mg + losartan 50mg
    • CCB intolerance: thiazide-like diuretic e.g. indapamide instead
    • The aim is to bring BP below stage 2 thresholds

  • Patients already on treatment should be managed according to the NICE algorithm

Antihypertensives on the day of surgery

  • Patients should continue all antihypertensives, including ACE-I and ARBs, on the day of surgery
    • This is a change from previous practice of withholding ACE-I/ARBs for 24hrs due to concerns about refractory intra-operative hypotension
    • Recent RCTs (SPACE and STOP-or-NOT) found no additional risk with continuation
  • Antihypertensives should not be stopped abruptly; inappropriate cessation of β-blockade is associated with an increased risk of silent ischaemia

Aetiology of intra-operative hypertension

Patient factors Non-patient factors
Pre-existing, poorly controlled essential HTN Excessive vasopressor use
Secondary HTN Inadequate anaesthesia/analgesia
Pain Malignant hyperpyrexia
Awareness Inappropriate BP cuff size or transducer height
Raised ICP Steep head down
Thyroid storm Surgical e.g. tumour handling in phaeochromocytoma resection
PET Use of ergometrine in PET

Cardiovascular management of the known hypertensive

  • In general, the cardiovascular system is more 'sensitive':
    • Labile blood pressure is more likely, especially in response to stimuli (intubation, surgical stimulus, extubation, post-operative pain)
    • Poorly controlled hypertensives often have a lower BP nadir after induction than normotensive patients
    • Exaggerated response to vasoactive medications
    • Poor tolerance of large fluid shifts; maintain intravascular volume

  • The organ sequelae of hypertension increase risks:
    • Right shift in organ autoregulatory curves make key circulations susceptible to hypotension e.g. cerebral, renal, coronary
    • Hypertrophied LV is at risk of subendocardial myocardial ischaemia if there is inadequate coronary perfusion pressure

Intra-operative hypotension

  • Associated with myocardial injury, AKI and increased mortality; the lower and longer the hypotension, the stronger the association with harm
  • However, RCTs of tighter BP control have produced mixed results, suggesting hypotension may be a marker as well as a mediator of harm
  • Thresholds commonly used to define hypotension:
    • MAP <60-70mmHg
    • SBP <100mmHg
    • A fall of >20% from baseline for >10min
  • Targeting an absolute value is easier in practice than targeting a value relative to baseline

Intra-operative management
Individualise BP targets to the patient and procedure
In higher-risk patients target MAP >70mmHg and/or SBP >100mmHg
Avoid excessive and prolonged hypotension
Reduce elevated BP cautiously
Shorten NIBP cycle intervals and adjust alarm limits
Low threshold for invasive arterial monitoring
Consider proactive (peripheral) vasopressor infusions
rather than reactive boluses, which increase BP variability
Avoid tachycardia

  • In high-risk patients, adjuncts such as cardiac output monitoring, processed EEG, NIRS and hypotension prediction monitors may help guide fluid and vasopressor therapy

  • Monitor BP regularly: post-operative hypo- and hypertension are both common and associated with adverse outcomes

Post-operative hypertension

  • Common on emergence: affects ~20% after elective non-cardiac surgery and up to 57-91% after intracranial surgery
  • Usually settles with treatment of the underlying cause: pain, anxiety, hypoxia, hypercarbia, hypothermia or fluid overload
  • If persistent, drugs include IV or topical GTN, magnesium, β-blockers and calcium channel blockers; hydralazine and sodium nitroprusside are used less frequently

Post-operative hypotension

  • Less well studied than intra-operative hypotension but associated with harm, especially if prolonged or occurring on post-operative days 1-4
  • Manage promptly with clinical assessment and targeted therapy, aiming for the patient's pre-operative BP

Reintroducing antihypertensives

  • Restart once BP has returned to the patient's normal values, guided by BP rather than by default
  • Consider reduced doses initially with subsequent titration; patients may not need their full doses during the inpatient stay
  • Lying and standing BP can guide reintroduction
  • Multimodal anti-emesis to enable patients to take oral medication
  • Document any changes and further titration required in the discharge letter for primary care review